Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angioedema
Fierce Biotech
BioCryst inks $700M Astria deal to rival Takeda in rare disease
The takeover will give the rare disease specialist control of a phase 3 challenger to Takeda’s hereditary angioedema therapy Takhzyro.
Nick Paul Taylor
Oct 14, 2025 10:30am
Ionis steps into crowded HAE market with FDA nod for Dawnzera
Aug 21, 2025 3:30pm
Fierce Biotech
FDA's 'heavy workload' blamed for delaying KalVista's PDUFA date
Jun 16, 2025 4:33am
New HAE drugs from Takeda, BioCryst are gaining popularity
Mar 18, 2022 11:16am
Samsung, Moderna, Brii and more—Fierce Pharma Asia
Aug 27, 2021 9:20am
ICER is urging steep discounts on Takeda and CSL drugs
Aug 24, 2021 2:18pm
